Recently, Hangzhou Sino-American Huadong Pharmaceutical Co., Ltd. (hereinafter referred to as “China-American Huadong”) and Huadong Pharmaceutical Investment Holdings (Hong Kong) Co., Ltd. (hereinafter referred to as “Huadong Pharmaceutical Investment Holdings”) and Ashvattha Therapeutic signed a joint equity agreement with Ashvattha Therapeutic. Investment agreement and product exclusive license agreement. According to the agreement, Huadong Pharmaceutical Investment Holdings will invest in phased investment subscriptions for the Series B preferred shares issued by Ashvattha. At the same time, Sino-US East China will obtain exclusive licenses for 8 products under research owned by Ashvattha in 20 Asian countries and regions including China, Singapore and Malaysia, including the use of Ashvattha's related intellectual property rights for R&D, production and commercialization rights.

Ashvattha is an innovative biopharmaceutical company focused on hydroxy dendrimer therapies (HDTs), founded by three scientists, namely: Dr. Kannan Rangaramanujam, who is a special appointment at the Wilmer Eye Institute of Johns Hopkins School of Medicine Professor and co-director of the Nanomedicine Center, with more than 15 years of experience in the development and verification of dendrimer platforms; Sujatha Kannan, MD, she is Professor of Anesthesiology, Critical Care Medicine and Pediatrics at Johns Hopkins University School of Medicine, her research focus It uses nanotechnology for imaging and targeted therapy of pediatric brain diseases; Dr. Jeffrey Cleland, who is a PhD in chemical engineering from MIT, has more than ten years of experience in new drug research and development.

Currently, Ashvattha is developing new therapies that target and change specific cells in the diseased tissue area. The company's platform technology, hydroxy dendrimer (HD), has obtained an exclusive license from Johns Hopkins University. HD is chemically conjugated with disease ameliorating drugs, forming a new proprietary HD therapy. Ashvattha has launched a number of HDTs projects, focusing on excessive inflammation in diseases such as tumors, age-related macular degeneration (AMD), COVID-19, and neuroinflammatory diseases such as amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. .

This time, Huadong Medicine introduced 8 products under research from Ashvattha Company, covering the treatment of tumors, metabolic comorbidities and inflammation. Among them, one product has entered Phase 2 clinical trials in the United States, and two products are scheduled to submit IND applications in the United States in the first quarter of 2022. Huadong Medicine believes that this cooperation will further enrich its innovative product pipeline in the fields of oncology, immunity and endocrinology.

According to the press release, the hydroxy dendrimer therapy developed by Ashvattha has good disease cell targeting. It can be administered systemically through oral, injection, etc., while selectively targeting the reactive cells of disease tissues, providing local sustained effects. , Benefit patients. In addition, dendrimers can pass through tissue barriers (such as blood-brain barrier and blood-retinal barrier) for the treatment of various diseases, and have the advantages of good safety, low off-target toxicity, and large-scale production.

Huadong Medicine pointed out in the press release that Ashvattha’s technology belongs to nanomedicine and nanomaterials. Its unique HD platform is currently the only hydroxy dendrimer platform capable of producing highly selective drugs in the world. The tissue barrier has the potential to develop a variety of therapeutic drugs. These products introduced this time will provide doctors and patients with more accurate and scientific diagnosis and treatment and medication options after they are launched in the future.